Competition between normal [674C] and mutant [674R]GPIIb subunits: Role of the molecular chaperone BiP in the processing of GPIIb-IIIa complexes

Blood

Volumn 97, Issue 9, 2001, Pages 2640-2647

  Arias Salgado, Elena G ^a   Butta, Nora ^a   González Manchón, Consuelo ^a   Larrucea, Susana ^a   Ayuso, Matilde S ^a   Parrilla, Roberta ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; DITHIOTHREITOL; FIBRINOGEN RECEPTOR; GLUCOSE REGULATED PROTEIN 78; PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL SURFACE; CHO CELL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; FLOW CYTOMETRY; GENE MUTATION; GENE OVEREXPRESSION; GLANZMANN DISEASE; HETEROZYGOSITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN TRANSPORT; THROMBOCYTE;

EID: 0035353156     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.9.2640     Document Type: Article

References (44)

1. Glanzmann E. Hereditare hemorrhagische thrombasthenie: ein beitrag zur pathologie der blut plattchen. J Kinderkr. 1918;88:113-141.
2. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75:1383-1395.
3. Phillips DR, Agin PP. Platelet membrane defects in Glanzmann's thrombasthenia: evidence for decreased amounts of two major glycoproteins. J Clin Invest. 1977;60:535-545.
4. Nurden AT, Rosa JP, Fournier D, et al. A variant of Glanzmann's thrombasthenia with abnormal GPIIb-IIIa complexes in the platelet membrane. J Clin Invest. 1987;79:962-969.
5. Caen JP. Glanzmann's thrombasthenia. Clin Haematol. 1972;1:383-392.
6. Fournier DJ, Kabral A, Castaldi PA, Berndt MC. A variant of Glanzmann's thrombasthenia characterized by abnormal glycoprotein IIb/IIIa complex formation. Thromb Haemost. 1989;62:977-983.
7. Heidenreich R, Eisman R, Delgrosso K, et al. The organization of the gene for platelet glycoprotein IIb. Biochemistry. 1990;29:1232-1244.
8. Fitzgerald LA, Steiner B, Rall SC, Lo S-S, Phillips DR. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone: identity with platelet glycoprotein IIIa and similarities to integrin. J Biol Chem. 1987;262:3936-3939.
9. Rosa J-P, Bray PF, Gayet O, et al. Cloning of glycoprotein IIIa cDNA from human erythroleukemic cells and localization of the gene to chromosome 17. Blood. 1988;71:593-600.
10. Lanza F, Kieffer N, Phillips DR, Fitzgerald LA. Characterization of the human platelet glycoprotein IIIa gene: comparison with the fibronectin receptor β-subunit gene. J Biol Chem. 1990;265:18098-19103.
11. Zimrin AB, Giditz S, Lord S, et al. The genomic organization of platelet glycoprotein IIIa. J Biol Chem. 1990;265:8590-8595.
12. French DL, Coller DS. Hematological important mutations: Glanzmann thrombasthenia. Blood Cells Mol Dis. 1997;23:39-51.
13. French DL. The molecular genetics of Glanzmann's thrombasthenia. Platelets. 1998;9:5-20.
14. González-Manchón C, Fernández-Pinel M, Arias-Salgado EG, et al. Molecular genetic analysis of a compound heterozygote for the glycoprotein (GP) IIb gene associated with Glanzmann's thrombasthenia: disruption of the 674-687 disulfide bridge in GPIIb prevents surface exposure of GPIIb-IIIa complexes. Blood. 1999;93:866-875.
15. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene. 1989;77:61-68.
16. Gulick T. Transfection using DEAE-dextran. In: Ausubel FM, Brent R, Kingston RE, et al, eds. Current Protocols in Molecular Biology. Vol 1. New York, NY: Wiley; 1997:9.2.1.
17. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
18. Ferrer M, Tao J, Iruin G, et al. Truncation of GPIIla (Δ 616-762) prevents complex formation with GPIIb: novel mutation in exon 11 of GPIIIa associated with thrombasthenia. Blood. 1998;92:4712-4720.
19. Ferrer M, Fernández M, González-Manchón C, González J, Ayuso MS, Parrilla R. A mutant (Arg327→His) GPIIb associated to thrombasthenia exerts a dominant negative effect in stably transfected CHO cells. Thromb Haemost. 1996;76:292-301.
20. Tao J, Arias-Salgado EG, González-Manchón C, et al. A 1063G→A mutation in exon 12 of GPIIb associated with thrombasthenic phenotype: mutation analysis of [324E] GPIIb. Br J Haematol. 2000;111:965-973.
21. Seckler R, Jaenicke R. Protein folding and protein refolding. FASEB J. 1992;6:2545-2552.
22. Calvete JJ, Alvarez MV, Rivas G, Hew C-L, Henschen A, González-Rodríguez J. Interchain and intrachain disulfide bonds and in human platelet glycoprotein IIb: localization of epitopes for several monoclonal antibodies. Biochem J. 1989;261:551-560.
23. Newman PJ, Seligsohn U, Lyman S, Coller BS. The molecular genetic basis of Glanzmann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci U S A. 1991;88:3160-3164.
24. French DL, Chen F, Xu L, Coller BS. A common Arg584Stop mutation in glycoprotein (GP)IIb in 2 additional patients with Glanzmann thrombasthenia [abstract]. Blood. 1993;88:30a.
25. 3) in a Chinese patient with Glanzmann's thrombasthenia. Blood. 1996;88:1666-1675.
26. Ambo H, Kamata T, Handa M, et al. Three novel integrin beta3 subunit missense mutations (H280P, C560F, G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients. Biochem Biophys Res Commun. 1998;251:763-768.
27. Ruan J, Schmugge M, Clemetson KJ, et al. Homozygous Cys542→Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann's thrombasthenia. Br J Haematol. 1999;105:523-531.
28. 3 is involved in an atypical case of Glanzmann thrombasthenia [abstract]. Throm Haemost. 1997;77:360a.
29. Wang R, Peterson J, Aster RH, Newman PJ. Disruption of a long-range disulfide bond between residues Cys406 and Cys655 in glycoprotein Ilia does not affect the function of platelet glycoprotein IIb-IIIa [letter]. Blood. 1997;90:1718-1719.
30. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
31. Gaut JR, Hendershot LM. The modification and assembly of proteins in the endoplasmic reticulum. Curr Opin Cell Biol. 1993;5:589-595.
32. Hartl FU. Molecular chaperones in cellular protein folding. Nature. 1996;381:571-580.
33. Ruddon RW, Bedows E. Assisted protein folding. J Biol Chem. 1997;272:3125-3128.
34. Frydman J, Hartl FU. Principles of chaperone-assisted protein folding: differences between in vitro and in vivo mechanisms. Science. 1996;272:1497-1502.
35. Hammond C, Helenius A. Folding of VSV G protein: sequential interaction with BIP and calnexin. Science. 1994;266:456-458.
36. Kim PS, Arvan P. Calnexin and BiP act as sequential molecular chaperones during thyroglobulin folding in the endoplasmic reticulum. J Cell Biol. 1995;128:29-38.
37. Khan MJ, Kieber-Emmons T, Vilaire G, Murali R, Poncz M, Bennett JS. Effect of mutagenesis of GPIIb amino acid 273 on the expression and conformation of the platelet integdn GPIIb-IIIa. Biochemistry. 1996;35:14304-14311.
38. Bedows E, Norton SE, Huth JR, Suganuma N, Boime I, Ruddon RW. Misfolded human chorionic gonadotropin beta subunits are secreted from transfected Chinese hamster ovary cells. J Biol Chem. 1994;269:10574-10580.
39. Hershkowitz I. Functional inactivation of genes by dominant negative mutations. Nature. 1987;329:219-222.
40. Sheppard D. Dominant negative mutants: tools for the study of protein function in vitro and in vivo. Am J Respir Cell Mol Biol. 1994;11:1-6.
41. Parrilla R, Mixson J, McPherson J, McClaskey J. Characterization of seven novel mutations of the c-erbA-β gene in patients with generalized thyroid hormone resistance. Evidence for two "hot spot" regions of the ligand binding domain. J Clin Invest. 1991;88:2123-2130.
42. Nagaya T, Jameson JL. Thyroid hormone receptor dimerization is required for dominant negative inhibition by mutations that cause thyroid hormone resistance. J Biol Chem. 1993;268:15766-15771.
43. Unger T, Mietz JA, Scheffiner M, Yee CL, Howley PM. Functional domains of wild type and mutant p53 proteins involved in transcriptional regulation transdominant inhibition and transformation suppression. Mol Cell Biol. 1993;13:5186-5194.
44. Frattali AL, Treadway JL, Pessin JE. Insulin/IGF-1 hybrid receptors: implications for the dominant negative phenotype in syndromes of insulin resistance. J Cell Biochem. 1992;48:43-50.